OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.

OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.

We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor. 


Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 8 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period).

Current Issue: 2022  Archive: 2021 2020 2019 2018 2017

Special Issue

Current Advancement of Islet Cell Transplantation in the Treatment of Diabetes Mellitus 2.0

Submission Deadline: March 15, 2023 (Open) Submit Now

Guest Editor

Preeti Chhabra, PhD

Department of Surgery, University of Virginia, Charlottesville, VA 22908, USA

Publications: https://www.ncbi.nlm.nih.gov/myncbi/preeti.chhabra.1/bibliography/public/

Website | E-Mail

Research Interests: Type 1 diabetes; immunotherapies; COVID-19 treatments; Micriobiome and microRNA biomarkers; Proteomics; Islet transplantation; Immunoglobulin M

About This Topic

Type 1 diabetes mellitus (T1DM) is caused by the autoimmune destruction of insulin-producing beta cells that results in the progressive loss of insulin secretion and glycometabolic control. According to the Collaborative Islet Transplant Registry, approximately 1.9 million Americans have T1DM, with this number expected to rise to 5 million by the year 2050. For patients with hyper-labile diabetes that experience recurrent life-threatening hypoglycemic episodes and reduced hypoglycemic awareness, and who are refractory to conventional means of stabilizing glycometabolic control, clinical islet transplantation represents a safe and effective treatment option. The benefits of the procedure include lowering of daily Insulin requirements, improved levels of glycated hemoglobin, reduced number of hypoglycemic episodes and unawareness, improved quality of life, and potential insulin independence. The remarkable advances made during the last decade indicate we are well on our way to transitioning clinical islet transplantation into a widespread and fundable option for curing T1DM.


Islet transplantation; Autotransplantation; Allotransplantation; Insulin independence; Hypoglycemic episodes; Pancreas procurement, islet processing and infusion characteristics; Induction and maintenance immunosuppression; Graft function; Immunotherapies; Strategies promoting graft survival; Stem cells